- Home
- IHRT vs TSHA Comparison
IHRT vs TSHA Comparison
Compare IHRT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHRT
- TSHA
- Stock Information
- Founded
- IHRT 1974
- TSHA 2019
- Country
- IHRT United States
- TSHA United States
- Employees
- IHRT N/A
- TSHA N/A
- Industry
- IHRT Broadcasting
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- IHRT Consumer Discretionary
- TSHA Health Care
- Exchange
- IHRT Nasdaq
- TSHA Nasdaq
- Market Cap
- IHRT N/A
- TSHA 397.8M
- IPO Year
- IHRT 2019
- TSHA 2020
- Fundamental
- Price
- IHRT $1.21
- TSHA $2.10
- Analyst Decision
- IHRT Buy
- TSHA Strong Buy
- Analyst Count
- IHRT 3
- TSHA 8
- Target Price
- IHRT $2.83
- TSHA $6.63
- AVG Volume (30 Days)
- IHRT 598.4K
- TSHA 2.9M
- Earning Date
- IHRT 05-12-2025
- TSHA 05-16-2025
- Dividend Yield
- IHRT N/A
- TSHA N/A
- EPS Growth
- IHRT N/A
- TSHA N/A
- EPS
- IHRT N/A
- TSHA N/A
- Revenue
- IHRT $3,854,532,000.00
- TSHA $8,333,000.00
- Revenue This Year
- IHRT $0.97
- TSHA N/A
- Revenue Next Year
- IHRT $5.09
- TSHA N/A
- P/E Ratio
- IHRT N/A
- TSHA N/A
- Revenue Growth
- IHRT 2.76
- TSHA N/A
- 52 Week Low
- IHRT $0.81
- TSHA $1.05
- 52 Week High
- IHRT $2.84
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- IHRT 51.94
- TSHA 58.01
- Support Level
- IHRT $1.02
- TSHA $1.85
- Resistance Level
- IHRT $1.09
- TSHA $2.73
- Average True Range (ATR)
- IHRT 0.08
- TSHA 0.27
- MACD
- IHRT 0.04
- TSHA 0.04
- Stochastic Oscillator
- IHRT 86.67
- TSHA 58.47
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.